Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada-Reference-Cited by-同舟云学术

Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada

Published:2022-09-22 Issue:38 Volume:27 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Kim Shinhye¹,Chuang Erica SY¹,Sabaiduc Suzana¹,Olsha Romy²,Kaweski Samantha E¹,Zelyas Nathan³,Gubbay Jonathan B⁴²,Jassem Agatha N⁵¹,Charest Hugues⁶,De Serres Gaston⁷⁸⁶,Dickinson James A⁹,Skowronski Danuta M⁵¹

Affiliation:

1. British Columbia Centre for Disease Control, Vancouver, Canada

2. Public Health Ontario, Toronto, Canada

3. Public Health Laboratory, Alberta Precision Laboratories, Edmonton, Canada

4. University of Toronto, Toronto, Canada

5. University of British Columbia, Vancouver, Canada

6. Institut national de santé publique du Québec, Québec, Canada

7. Centre Hospitalier Universitaire de Québec, Québec, Canada

8. Laval University, Quebec, Canada

9. University of Calgary, Calgary, Canada

Abstract

Influenza virus circulation virtually ceased in Canada during the COVID-19 pandemic, re-emerging with the relaxation of restrictions in spring 2022. Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network reports 2021/22 vaccine effectiveness of 36% (95% CI: −38 to 71) against late-season illness due to influenza A(H3N2) clade 3C.2a1b.2a.2 viruses, considered antigenically distinct from the 3C.2a1b.2a.1 vaccine strain. Findings reinforce the World Health Organization’s decision to update the 2022/23 northern hemisphere vaccine to a more representative A(H3N2) clade 3C.2a1b.2a.2 strain.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference15 articles.

1. The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: A population-based study.;Groves;Lancet Reg Health Am,2021

2. Public Health Agency of Canada (PHAC). Influenza weekly reports 2021-22 season. Ottawa: PHAC; 2022. [Accessed 6 September 2022]. Available from: https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/diseases-conditions/fluwatch/2021-2022/weeks-30-34-july-24-august-27-2022/fluwatch-weeks-30-34.pdf

3. Effects of confounding bias in coronavirus disease 2019 (COVID-19) and influenza vaccine effectiveness test-negative designs due to correlated influenza and COVID-19 vaccination behaviors.;Doll;Clin Infect Dis,2022

4. Canadian Influenza Sentinel Practitioner Surveillance Network (SPSN). Influenza vaccine effectiveness estimates % (95% CI), 2004-05 to 2018-19 seasons. Vancouver: British Columbia Centre for Disease Control. [Accessed: 6 September 2022]. Available from: http://www.bccdc.ca/resource-gallery/Documents/Statistics%20and%20Research/Publications/Epid/Influenza%20and%20Respiratory/SPSN_VE_By_Year_Table.pdf

5. World Health Organization (WHO). Recommendations for influenza vaccine composition; 2022. [Accessed 18 September 2022]. Available from: https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influenza virus circulation and vaccine effectiveness during June 2021–May 2023 in Thailand;Vaccine: X;2024-08

2. Wastewater Surveillance to Confirm Differences in Influenza A Infection between Michigan, USA, and Ontario, Canada, September 2022–March 2023;Emerging Infectious Diseases;2024-08

3. Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season;Eurosurveillance;2024-01-11

4. Influenza Vaccine Effectiveness against Hospitalization, Season 2021/22: A Test-Negative Design Study in Barcelona;Vaccines;2023-09-02

5. Seasonal Influenza Vaccine Effectiveness in Persons Aged 15–64 Years: A Systematic Review and Meta-Analysis;Vaccines;2023-08-04